This study is a Phase III, double-blind, placebo-controlled, multi-arm platform study that will enroll participants from Brasil, Canada, Italy, Uganda, Zambia, and the United States. The first phase, involving 348 participants, will investigate two repurposed drugs over a 3-month period, each paired with its own placebo, followed by an interim analysis. After completing the 3-month treatment, the original 348 participants will be monitored for an additional 3 months for symptom rebound and safety. The second phase, guided by the results of the first phase, will be followed by a final analysis. In this phase, the study may continue with one or both repurposed drugs, combine one with an add-on repurposed drug, or introduce completely new repurposed drug(s).
Expected Impact: Identify safe and effective drugs for treatment of post-COVID disease.
